Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies
John Magenau(University of Michigan), Shin Mineishi(University of Alabama at Birmingham), Attaphol Pawarode(University of Michigan), Kojo S.J. Elenitoba‐Johnson(Memorial Sloan Kettering Cancer Center), David Frame(Rush University), James L.M. Ferrara(Tisch Hospital), Andrew C. Harris(Primary Children's Hospital), Thomas Braun(Justus-Liebig-Universität Gießen), John E. Levine(Icahn School of Medicine at Mount Sinai), Harry P. Erba(Michigan Center for Translational Pathology), Sophie Paczesny(MUSC Hollings Cancer Center), Sung Won Choi(University of Michigan), Carrie L. Kitko(Vanderbilt University Medical Center), Pavan Reddy(Wichita State University), Jennifer Sanks(University of Michigan), Gregory A. Yanik(University of Michigan), Dawn Jones(University of Michigan), Lisa Kujawski, Edward Peres(Henry Ford Hospital), Hiromi Tobai(NHS Blood and Transplant)
Cited by 57
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735